Document Detail


The tyramine binding site in the central nervous system: an overview.
MedLine Citation:
PMID:  8396735     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The [3H]Tyramine (TY) binding site is proposed as a high affinity marker of the membrane carrier for dopamine (DA) in synaptic vesicles from DA-rich brain regions. Under precise assay conditions, there is neither a consistent association of TY with the neuronal, cocaine-sensitive DA transporter, nor with mitochondrial or microsomal targets. TY-labeled sites have a high affinity for selected toxins such as the Parkinsonian agent MPP+ (1-methyl-4-phenylpyridinium ion), or drugs such as diphenylalkylamine Ca(2+)-channel antagonists. The MPP+/TY site interaction, which in the striatum leads to depletion of vesicular DA, occurs in dopaminergic as well as in noradrenergic regions, though with different kinetic profiles. TY-labeled carriers for DA and noradrenaline (NA) in respective vesicles seem to be different entities, which might result in a region-specific rate of toxin sequestration and/or release from heterogeneous vesicles. Whereas MPP+ is a potent competitive-type inhibitor of [3H]TY binding, prenylamine-like Ca(2+)-channel antagonists can compete with TY for the vesicle site, in a tetrabenazine- or reserpine-like manner, and also inhibit TY binding thanks to the extra-channel directed impairment of membrane bioenergetics they are proposed to provoke. This follows from the generally-accepted assumption that similar mechanisms are operational for secretory organelles in adrenals and CNS, and from the marked sensitivity of TY binding to miscellaneous energy-disrupting agents.(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
A Vaccari
Related Documents :
12112405 - Parametric mapping of [18f]fpcit binding in early stage parkinson's disease: a pet study.
16392815 - Design and synthesis of photoaffinity-labeling ligands of the l-prolyl-l-leucylglycinam...
23271735 - Alteration of tropomyosin-binding properties of tropomodulin-1 affects its capping abil...
24779955 - Prediction of high and low affinity quinol-analogs binding sites in the aa3 and bo3 ter...
25460685 - Role of ion-pair interactions on asphaltene stabilization by alkylbenzenesulfonic acids.
24858095 - In silico docking, molecular dynamics and binding energy insights into the bolinaquinon...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Neurochemical research     Volume:  18     ISSN:  0364-3190     ISO Abbreviation:  Neurochem. Res.     Publication Date:  1993 Aug 
Date Detail:
Created Date:  1993-10-08     Completed Date:  1993-10-08     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  7613461     Medline TA:  Neurochem Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  861-8     Citation Subset:  IM    
Affiliation:
Department of Neuroscience, B. Brodie, Cagliari, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / pharmacology
Animals
Binding Sites
Brain / metabolism*
Calcium Channel Blockers / pharmacology
Dopamine / metabolism
Humans
Receptors, Biogenic Amine*
Receptors, Neurotransmitter / drug effects,  metabolism*
Tyramine / metabolism*
Chemical
Reg. No./Substance:
0/Calcium Channel Blockers; 0/Receptors, Biogenic Amine; 0/Receptors, Neurotransmitter; 0/tyramine receptor; 28289-54-5/1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 51-67-2/Tyramine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes.
Next Document:  Electric shock convulsions in the rabbit and brain cortex GABAA receptor function.